HOME PRODUCTS COMPANY CONTACT FAQ

Research Dictionary Pharma

Sign Up FREE or Login

ABI 0043

structure in first source

Also Known As:

ABI-0043; ABI0043

Networked: 2 relevant articles (2 outcomes, 0 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Heterocyclic Compounds: 198
- Fused-Ring Heterocyclic Compounds
  - 4 or More Rings Heterocyclic Compounds
    - Rifamycins: 416
      - ABI 0043: 2
Polycyclic Compounds: 6
- Macrocyclic Compounds: 15
  - Macrocyclic Lactams: 28
    - Rifamycins: 416
      - ABI 0043: 2

Experts

1.	Murphy, Christopher K: 2 articles (07/2007 - 12/2006)
2.	Landmann, Regine: 1 article (07/2007)
3.	Rothstein, David M: 1 article (07/2007)
4.	Trampuz, Andrej: 1 article (07/2007)
5.	Widmer, Andreas F: 1 article (07/2007)
6.	Zimmerli, Werner: 1 article (07/2007)
7.	Lee, Su Young: 1 article (12/2006)
8.	Nicolau, David P: 1 article (12/2006)
9.	Tessier, Pamela R: 1 article (12/2006)

Related Diseases

1.	Pneumococcal Pneumonia 12/01/2006 - "Bactericidal efficacy of ABI-0043, a novel rifamycin, in a murine pneumococcal pneumonia model."
2.	Infections 07/01/2007 - "ABI-0043 in combination with a quinolone has the potential for treatment of implant-associated infections caused by susceptible strains of S. " 07/01/2007 - "Efficacy of a novel rifamycin derivative, ABI-0043, against Staphylococcus aureus in an experimental model of foreign-body infection." 07/01/2007 - "The cure rates of cage-associated infections with rifampin and ABI-0043 administered alone were 46% and 58%, respectively, and increased to 88% and 92% in combination with levofloxacin. " 07/01/2007 - "We compared the efficacy of a novel rifamycin derivative, ABI-0043, with that of rifampin, alone and in combination with levofloxacin, against methicillin-susceptible Staphylococcus aureus ATCC 29213 in a guinea pig tissue-cage infection model. "
3.	Foreign Bodies (Foreign Body) 07/01/2007 - "Efficacy of a novel rifamycin derivative, ABI-0043, against Staphylococcus aureus in an experimental model of foreign-body infection."
4.	Pneumonia (Pneumonitis) 12/01/2006 - "Novel rifamycins such as ABI-0043, ABI-0369, and ABI-0699 had comparable in vivo bactericidal activity with ceftriaxone against a penicillin-G-resistant, mefA-positive Streptococcus pneumoniae in a murine pneumonia model. "
5.	Body Weight (Weight, Body) 07/01/2007 - "After a single intraperitoneal dose of 12.5 mg/kg of body weight, the peak concentration in cage fluid was 1.13 micarog/ml of ABI-0043 and 0.98 microg/ml of rifampin. "

Related Drugs and Biologics

1.	Rifamycins
2.	Levofloxacin (Levaquin)
3.	Rifampin (Rifampicin)
4.	Methicillin (Metin)
5.	Quinolones
6.	Penicillin G (Benzylpenicillin)
7.	Ceftriaxone (Ceftriaxon)

Related Therapies and Procedures

1.	Culture Diffusion Chambers